Lumigan - Comprehensive Usage Guide: instructions, indications, composition, side effects

Active Ingredient: Bimatoprost
Excipients: May include benzalkonium chloride, sodium chloride, sodium phosphate dibasic, citric acid, and other inactive ingredients depending on the formulation.

Eye Drops: Available in various concentrations, including 0.01% and 0.03% bimatoprost.

Lumigan belongs to the pharmacological group of prostaglandin analogs (ATC code: S01E E03).

• Pharmacodynamics: Bimatoprost lowers intraocular pressure (IOP) by increasing the outflow of aqueous humor through both the trabecular meshwork and uveoscleral pathways.
• Pharmacokinetics: After ocular administration, bimatoprost is absorbed systemically. Peak plasma concentrations are reached within 10 minutes. It undergoes hepatic metabolism and is excreted primarily in the urine.

Lumigan is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Lumigan is contraindicated in individuals with:

• Hypersensitivity to bimatoprost or any component of the formulation.
• Active intraocular inflammation (e.g., uveitis).
• Known risk factors for macular edema.

Lumigan may interact with other medications, including:

• Prostaglandin analogs, beta-blockers, or carbonic anhydrase inhibitors, potentially leading to additive effects on intraocular pressure reduction.
• Contact lenses should be removed before administration and may be reinserted after 15 minutes.

• Lumigan eye drops should be instilled into the affected eye(s) according to the prescribed dosage regimen.
• Shake the bottle well before each use and avoid touching the dropper tip to any surface to prevent contamination.

• Lumigan should be used during pregnancy only if the potential benefits outweigh the potential risks to the fetus.
• It is not recommended during breastfeeding due to limited data on its excretion into breast milk.

• The recommended dosage is one drop of Lumigan in the affected eye(s) once daily, preferably in the evening.

In case of overdose, supportive measures should be initiated, and medical attention should be sought immediately. Symptoms of overdose may include ocular irritation, conjunctival hyperemia, and eye pain.

Common side effects of Lumigan may include:

• Ocular irritation (e.g., burning, stinging, itching)
• Conjunctival hyperemia (redness)
• Blurred vision
• Dry eye
• Foreign body sensation

Less common but more severe adverse reactions may include:

• Allergic reactions (e.g., rash, itching, swelling)
• Conjunctival follicles
• Eyelash growth
• Iris pigmentation
• Periorbital skin darkening
• Visual disturbances

If any of these side effects persist or worsen, patients should discontinue use and consult their healthcare provider promptly. Additionally, patients should seek medical attention if they experience any signs of systemic absorption, such as changes in heart rate, blood pressure, or mental status.